Skip to main content
Premium Trial:

Request an Annual Quote

SQI, Algorithme Building Assay for Heparin Immunogenicity Testing

NEW YORK (GenomeWeb News) – SQI Diagnostics and Algorithme Pharma today said they are co-developing a proof-of-concept assay for immunogenicity testing of heparin and heparin-based low molecular weight biosimilar compounds.

The assay is based on SQI's Ig Plex multiplexing technology and is expected to be available on all of the Toronto-based firm's fully automated analytical systems, including its SQIDlite and SQIDworks platforms.

The test will provide drug developers and contract research organizations quantitative results for all three isotopes of heparin-induced thrombocytopenia (HIT) antibodies in a single test, SQI and Algorithme said. Using SQI's automated platform will also improve the benefits of multiplexing and reduce the time and labor necessary to process and analyze blood samples during the drug development and immunogenicity testing, they added.

"Because HIT antibodies are potentially produced with all heparin-based biosimilars, Algorithme, with this proof of concept completed, will have a 'shelf-ready' multiplexed assay ready to implement and deliver very competitive HIT testing to the many pharmaceutical companies who are building heparin biosimilar compounds," Robert Masse, vice president of Large Molecule Bioanalysis of Aligorithme Pharma, said in a statement.

Based in Laval, Quebec, Algorithme provides early stage clinical development studies to pharmaceutical and biotechnology companies.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more